Equillium Inc (EQ)

$2.08 +0.03 (1.46%)
Market Cap 136.57M
Revenue (ttm) 0.00
Net Income (ttm) -22.40M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 303,214
Avg Vol 481,328
Day's Range N/A - N/A
Shares Out 63.23M
Stochastic %K 34%
Beta 1.75
Analysts Strong Sell
Price Target $6.38

Company Profile

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 240 1200
Address:
2223 Avenida De La Playa, Suite 105, La Jolla, United States
SuperGreenToday
SuperGreenToday Apr. 28 at 3:47 PM
$EQ Share Price: $2.05 Contract Selected: Oct 16, 2026 $2.5 Calls Buy Zone: $0.42 – $0.53 Target Zone: $0.72 – $0.88 Potential Upside: 61% ROI Time to Expiration: 170 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BillionerOfKing
BillionerOfKing Apr. 28 at 12:02 PM
$EQ Current Stock Price: $2.04 Contracts to trade: $2.5 EQ May 15 2026 Call Entry: $0.23 Exit: $0.37 ROI: 59% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
FlyingTargets
FlyingTargets Apr. 27 at 8:41 PM
$EQ $ALIT $ENSC $KIDZ insane!
2 · Reply
BanditQ
BanditQ Apr. 24 at 6:55 PM
$EQ There is no doubt the drug works, it's just a matter of safety concerns, hopefully the enteric coating will do its thing.
1 · Reply
AceofDiamonds
AceofDiamonds Apr. 24 at 6:16 PM
$EQ And another analyst. Huge money is going to be made https://m.investing.com/news/analyst-ratings/oppenheimer-initiates-equillium-stock-with-outperform-on-uc-drug-93CH-4631898?ampMode=1
0 · Reply
LordFawkwadReturns
LordFawkwadReturns Apr. 22 at 7:18 PM
$EQ
0 · Reply
Publicola29
Publicola29 Apr. 20 at 4:12 PM
$EQ so they're voting on a reverse split and to increase outstanding shares to 400M?
1 · Reply
BanditQ
BanditQ Apr. 20 at 12:10 PM
$NKTR , $EQ is next
1 · Reply
BanditQ
BanditQ Apr. 17 at 10:26 AM
$EQ retail will jump in after the "first patient dosed" PR. should be this june-july.
0 · Reply
BanditQ
BanditQ Apr. 16 at 4:05 PM
$EQ https://www.marketbeat.com/instant-alerts/equillium-nasdaqeq-earns-buy-rating-from-analysts-at-b-riley-financial-2026-04-16/
0 · Reply
Latest News on EQ
Equiniti (EQ) Launches DealTrax™: A Digital-First Platform for Corporate Actions and M&A Events

Apr 28, 2026, 9:30 AM EDT - 1 day ago

Equiniti (EQ) Launches DealTrax™: A Digital-First Platform for Corporate Actions and M&A Events

Equillium to Participate in Oppenheimer's 2026 Innovation on the Island Event

Apr 20, 2026, 4:05 PM EDT - 9 days ago

Equillium to Participate in Oppenheimer's 2026 Innovation on the Island Event

Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists

Apr 8, 2026, 8:30 AM EDT - 21 days ago

Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 2, 2026, 4:05 PM EDT - 27 days ago

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights

Mar 25, 2026, 4:05 PM EDT - 5 weeks ago

Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights

Equillium to Participate in the 38th Annual Roth Conference

Mar 18, 2026, 8:30 AM EDT - 6 weeks ago

Equillium to Participate in the 38th Annual Roth Conference

Equillium Announces $35 Million Financing with RA Capital Management

Mar 13, 2026, 8:00 AM EDT - 6 weeks ago

Equillium Announces $35 Million Financing with RA Capital Management

Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference

Feb 25, 2026, 8:30 AM EST - 2 months ago

Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference

Equillium Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Feb 12, 2026, 3:30 PM EST - 2 months ago

Equillium Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Equillium to Participate in Upcoming Investor Conferences

Nov 20, 2025, 4:35 PM EST - 5 months ago

Equillium to Participate in Upcoming Investor Conferences

Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update

Nov 13, 2025, 4:05 PM EST - 5 months ago

Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update

Equillium Transcript: KOL Event

Nov 5, 2025, 12:00 PM EST - 6 months ago

Equillium Transcript: KOL Event

Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025

Oct 22, 2025, 8:00 AM EDT - 6 months ago

Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025

Equillium Announces Leadership and Corporate Updates

Oct 6, 2025, 4:02 PM EDT - 7 months ago

Equillium Announces Leadership and Corporate Updates

NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor

Sep 23, 2025, 5:30 AM EDT - 7 months ago

NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor

Equillium Transcript: Cantor Global Healthcare Conference 2025

Sep 5, 2025, 7:55 AM EDT - 8 months ago

Equillium Transcript: Cantor Global Healthcare Conference 2025

Equillium to Participate in the Cantor Global Healthcare Conference 2025

Aug 29, 2025, 4:03 PM EDT - 8 months ago

Equillium to Participate in the Cantor Global Healthcare Conference 2025

Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic

Aug 11, 2025, 8:30 AM EDT - 9 months ago

Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic

Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy

Aug 4, 2025, 8:30 AM EDT - 9 months ago

Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy

Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists

May 6, 2025, 8:00 AM EDT - 1 year ago

Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists

Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

May 1, 2025, 8:00 AM EDT - 1 year ago

Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

Equillium Announces Feedback from the U.S. Food and Drug Administration

Apr 24, 2025, 9:00 AM EDT - 1 year ago

Equillium Announces Feedback from the U.S. Food and Drug Administration

Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients

Mar 27, 2025, 11:16 AM EDT - 1 year ago

Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients

Equillium Transcript: Study Result

Mar 27, 2025, 8:30 AM EDT - 1 year ago

Equillium Transcript: Study Result

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

Feb 6, 2025, 8:00 AM EST - 1 year ago

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

Nov 13, 2024, 4:01 PM EST - 1 year ago

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

Equillium to Present at the Stifel Healthcare Conference

Nov 13, 2024, 8:00 AM EST - 1 year ago

Equillium to Present at the Stifel Healthcare Conference

Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer

Nov 12, 2024, 8:00 AM EST - 1 year ago

Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer

Equillium Maintains Rights to Itolizumab Following Ono Partnership

Oct 31, 2024, 7:00 AM EDT - 1 year ago

Equillium Maintains Rights to Itolizumab Following Ono Partnership

Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer

Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit

Equillium Transcript: H.C. Wainwright 26th Annual Global Investment Conference

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Equillium Transcript: H.C. Wainwright 26th Annual Global Investment Conference

Equillium Transcript: 2024 Wells Fargo Healthcare Conference

Sep 5, 2024, 4:30 PM EDT - 1 year ago

Equillium Transcript: 2024 Wells Fargo Healthcare Conference

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference

Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights

Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance

Jul 18, 2024, 1:57 PM EDT - 1 year ago

Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance

Equillium to be included in the Russell Microcap® Index

Jun 12, 2024, 8:00 AM EDT - 2 years ago

Equillium to be included in the Russell Microcap® Index

Equillium Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 10:30 AM EDT - 2 years ago

Equillium Transcript: Jefferies 2024 Global Healthcare Conference

Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata

Jun 4, 2024, 8:00 AM EDT - 2 years ago

Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata

Equillium to Present at the Jefferies Global Healthcare Conference

May 29, 2024, 8:00 AM EDT - 2 years ago

Equillium to Present at the Jefferies Global Healthcare Conference

Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

May 14, 2024, 8:00 AM EDT - 2 years ago

Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights

May 9, 2024, 4:01 PM EDT - 2 years ago

Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

May 7, 2024, 8:00 AM EDT - 2 years ago

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

Equillium Transcript: 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference 2024

Mar 28, 2024, 2:00 PM EDT - 2 years ago

Equillium Transcript: 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference 2024

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

Mar 25, 2024, 4:01 PM EDT - 2 years ago

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference

Mar 22, 2024, 8:00 AM EDT - 2 years ago

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

Dec 21, 2023, 8:00 AM EST - 2 years ago

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

Nov 13, 2023, 9:00 AM EST - 2 years ago

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Nov 8, 2023, 4:01 PM EST - 2 years ago

Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Nov 6, 2023, 8:00 AM EST - 2 years ago

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology

Equillium Transcript: R&D Day 2023

Oct 16, 2023, 12:00 PM EDT - 2 years ago

Equillium Transcript: R&D Day 2023

Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium

Equillium to Host Analyst & Investor Day

Oct 3, 2023, 8:00 AM EDT - 2 years ago

Equillium to Host Analyst & Investor Day

SuperGreenToday
SuperGreenToday Apr. 28 at 3:47 PM
$EQ Share Price: $2.05 Contract Selected: Oct 16, 2026 $2.5 Calls Buy Zone: $0.42 – $0.53 Target Zone: $0.72 – $0.88 Potential Upside: 61% ROI Time to Expiration: 170 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BillionerOfKing
BillionerOfKing Apr. 28 at 12:02 PM
$EQ Current Stock Price: $2.04 Contracts to trade: $2.5 EQ May 15 2026 Call Entry: $0.23 Exit: $0.37 ROI: 59% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
FlyingTargets
FlyingTargets Apr. 27 at 8:41 PM
$EQ $ALIT $ENSC $KIDZ insane!
2 · Reply
BanditQ
BanditQ Apr. 24 at 6:55 PM
$EQ There is no doubt the drug works, it's just a matter of safety concerns, hopefully the enteric coating will do its thing.
1 · Reply
AceofDiamonds
AceofDiamonds Apr. 24 at 6:16 PM
$EQ And another analyst. Huge money is going to be made https://m.investing.com/news/analyst-ratings/oppenheimer-initiates-equillium-stock-with-outperform-on-uc-drug-93CH-4631898?ampMode=1
0 · Reply
LordFawkwadReturns
LordFawkwadReturns Apr. 22 at 7:18 PM
$EQ
0 · Reply
Publicola29
Publicola29 Apr. 20 at 4:12 PM
$EQ so they're voting on a reverse split and to increase outstanding shares to 400M?
1 · Reply
BanditQ
BanditQ Apr. 20 at 12:10 PM
$NKTR , $EQ is next
1 · Reply
BanditQ
BanditQ Apr. 17 at 10:26 AM
$EQ retail will jump in after the "first patient dosed" PR. should be this june-july.
0 · Reply
BanditQ
BanditQ Apr. 16 at 4:05 PM
$EQ https://www.marketbeat.com/instant-alerts/equillium-nasdaqeq-earns-buy-rating-from-analysts-at-b-riley-financial-2026-04-16/
0 · Reply
Capitulation_0
Capitulation_0 Apr. 16 at 2:14 PM
$EQ flirting with staying above $2 for the 3rd of 4th time. I like the story here.
0 · Reply
BanditQ
BanditQ Apr. 16 at 1:57 PM
$ABVX $EQ $PALI far more upside potential with $EQ , given its a single asset company. $8+ after phase 1 data, ALL IN.
1 · Reply
Yimmiedd
Yimmiedd Apr. 16 at 1:28 PM
$EQ $PALI $ABVX Imagine not investing in all three of these 🤡
0 · Reply
Stocktwits019475
Stocktwits019475 Apr. 16 at 12:24 AM
$PALI Imagine investing in $EQ and not $PALI 😆😆😆
1 · Reply
BanditQ
BanditQ Apr. 14 at 12:57 PM
$EQ patience.
0 · Reply
AceofDiamonds
AceofDiamonds Apr. 14 at 12:51 PM
$EQ And another one. Huge money is gonna be made here. https://m.za.investing.com/news/stock-market-news/raymond-james-initiates-equillium-stock-coverage-with-strong-buy-93CH-4209583?ampMode=1
0 · Reply
DARKP00L
DARKP00L Apr. 14 at 11:49 AM
$EQ 07:36 on Apr. 14 2026 Raymond James Initiates Coverage On Equillium with Strong Buy Rating, Announces Price Target of $6 #tradeideas
0 · Reply
AceofDiamonds
AceofDiamonds Apr. 11 at 7:27 PM
$EQ Another Analyst at Cantor Fitzgerald just gave Equillium a $10.00 price target. https://www.marketbeat.com/instant-alerts/cantor-fitzgerald-begins-coverage-on-equillium-nasdaqeq-2026-04-07/
0 · Reply
Word0025
Word0025 Apr. 6 at 2:46 PM
$EQ SMALL RUN AT ALMOST 5% GAIN
0 · Reply
Word0025
Word0025 Apr. 6 at 1:25 PM
$EQ HAD PREMARKET EARNINGS
0 · Reply
focafoca99
focafoca99 Apr. 3 at 8:28 PM
$EQ granted inducement stock options covering 32,000 shares to a new employee.
0 · Reply
focafoca99
focafoca99 Mar. 31 at 1:50 AM
$EQ's proxy is not just routine AGM paper; it also asks shareholders to approve a possible reverse split of anywhere from 1-for-2 to 1-for-20.
0 · Reply